Ernexa Therapeutics Inc.
ERNA · NASDAQ
Market closed$5.43$-0.990000 (-15.42%)After hours $5.35 · -1.47%
Key statistics
Previous close$6.42
Open$6.19
Day high$6.35
Day low$5.33
52-week high$71.50
52-week low$3.18
Market cap1.71M
Volume242.07K
Average volume2.11M
P/E ratio-0.68
Forward P/E—
EPS-7.96
Dividend yield0.00%
Market context
Why it moved
ERNA shares declined sharply today, likely driven by broader market risk-off sentiment amid escalating US-Iran military tensions, which weighed on small-cap stocks and triggered a selloff across speculative positions.
What is happening
Recent company-specific developments and publisher coverage.
GlobeNewswire · July 15, 2026Ernexa Therapeutics Receives Independent Validation ofStocksToTrade · July 15, 2026ERNA Stock Pops As Ernexa Flags Progress Toward First TrialsStocksToTrade · July 15, 2026ERNA Stock Whipsaws As Ernexa Maps Path To First Human TrialInvesting.com · July 15, 2026Ernexa Therapeutics stock surges 30% on preclinical dataStock Titan · July 14, 2026Preclinical ovarian models: Ernexa's ERNA-101 cleared tumors with PD-1 blockadeInvesting.com Nigeria · July 14, 2026Ernexa plans IND filing for ovarian cancer therapy ERNA-101 By Investing.comGlobeNewswire · June 25, 2026Ernexa Therapeutics Launches CEO Corner to Provide DeeperPluang · May 20, 2026Ernexa Therapeutics highlights ERNA-101's poten... Benzinga · July 15, 2026Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy Mt Newswire · July 15, 2026Ernexa Therapeutics Says Preclinical Data Shows Anti-Tumor Activity of ERNA-101 Combination Benzinga · July 15, 2026Ernexa Therapeutics Announces Independently Conducted Study Validating Anti-Tumor Activity Of Its ERNA-101 Lead Cell Therapy Candidate Shows Complete Tumor Clearance, Durable Long-Term Survival; Investigational New Drug Submission Planned In Q3 Mt Newswire · June 17, 2026Ernexa Therapeutics Says Investigational New Drug Submission for ERNA-101 on Track for Q3 Benzinga · June 17, 2026Ernexa Therapeutics Advances ERNA-101 Toward IND Filing In Q3 2026; Targeting Phase 1 Cancer Trial Initiation In Q4 2026 Benzinga · May 27, 2026Ernexa Therapeutics Announces Progress In Development Of ERNA-101; Hits Multiple Milestones Ahead Of Planned IND Submission In Q3 2026 And First‑In‑Human Study Initiation Benzinga · May 12, 2026Ernexa Stock Is Jumping Today: What's Going On? Benzinga · May 7, 2026Brookline Capital Initiates Coverage On Ernexa Therapeutics with Buy Rating, Announces Price Target of $30